Nurix Therapeutics (NRIX)

• Market cap: $997M
• 1 day: -9.63%
• 5 days: -6.74%
• 1 month: -25.21%
• 3 months: -35.18%
• 6 months: -47.02%
• Year to date: -32.65%
• 1 year: -9.25%
• 5 years: -30.88%
• 10 years: -30.88%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Employees: 286

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

771% more call options, than puts

Call options by funds: $7.17M | Put options by funds: $823K

40% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 47

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

19% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 31

9.47% more ownership

Funds ownership: 105.0% [Q3] → 114.47% (+9.47%) [Q4]

2% more funds holding

Funds holding: 171 [Q3] → 174 (+3) [Q4]

1% more capital invested

Capital invested by funds: $1.52B [Q3] → $1.53B (+$8.01M) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 29% upside
• Avg. target: $29 123% upside
• High target: $36 174% upside

7 analyst ratings

• positive: 6 86%
• neutral: 1 14%
• negative: 0 0%

Morgan Stanley Terence Flynn 42% 1-year accuracy 8 / 19 met price target	29% upside $17	Equal-Weight Maintained	3 Feb 2025
RBC Capital Gregory Renza 37% 1-year accuracy 28 / 76 met price target	105% upside $27	Outperform Maintained	29 Jan 2025
JP Morgan Eric Joseph 46% 1-year accuracy 12 / 26 met price target	128% upside $30	Overweight Maintained	29 Jan 2025
Stifel Stephen Willey 26% 1-year accuracy 5 / 19 met price target	174% upside $36	Buy Maintained	29 Jan 2025
Needham Gil Blum 9% 1-year accuracy 15 / 164 met price target	113% upside $28	Buy Maintained	29 Jan 2025